Table 1.
Summary of cell-surface molecules for targeted therapy and ongoing clinical trials in NKTCL patients
| Agent | Target | Trial ID | Patient number (evaluable /estimate) | Study phase | Combined agents | Indication | Results for NKTCL | References | |
|---|---|---|---|---|---|---|---|---|---|
| Cell-surface-targeted antibodies | Daratumumab | CD38 | NCT02927925 | 32 | 2 | / | r/r NKTCL |
ORR:25%, CR:0% 4-m PFS:13% 6-m OS:42.9% |
[16] |
| Isatuximab | CD38 | NCT04763616 | 37 | 2 | Cemiplimab | r/r NKTCL | / | / | |
| Basiliximab | CD25 | NCT04337593 | 30 | 2 | Pegaspargase | r/r NKTCL | / | / | |
| Alemtuzumab | CD52 | NCT00069238 | 31 | 2 | EPOCH | Untreated T and NK-cell lymphoma | / | / | |
| Brentuximab vedotin | CD30 | NCT02280785 | 33 (7 NKTCL) | 2 | / | r/r CD30-expressing NHL | ORR:29% | [22] | |
| Brentuximab vedotin | CD30 | NCT03246750 | 36 | 1/2 | MAD | Newly diagnosed ENKTL | / | / | |
| CAR-T Therapy | CD30.CAR-T | CD30 | NCT04526834 | 21 | 1 | r/r CD30 positive NHL | / | / | |
| CD30.CAR-T | CD30 | NCT03049449 | 26 | 1 | Cyclophosphamide Fludarabine | CD30 expressing lymphomas | / | / | |
| CD30.CAR-EBVSTs | CD30 | NCT04288726 | 18 | 1 | r/r CD30 positive NHL | / | / | ||
| EBV targeted CTL | Baltaleucel-T | EBV antigens | NCT01948180 | 15 | 2 | Advanced ENKTL |
Salvage cohort: ORR:50% CR:30% |
[73] | |
| VT-EBV-N | LMP | NCT03671850 | 48 | 2 | EBV positive NKTCL | ||||
NKTCL: natural killer/T-cell lymphoma, ORR: objective response rate, CR: complete remission, OS: overall survival, PFS: progression-free survival, EPOCH: etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin, NHL: non-Hodgkin lymphoma, MAD: methotrexate, L-asparaginase, and dexamethasone, ENKTL: extranodal natural killer/T- cell lymphoma, CAR: chimeric antigen receptor, CTL: cytotoxic T lymphocyte, EBV: Epstein-Barr virus, LMP: latent membrane protein